Last reviewed · How we verify

NCT04748822: QUALIFACT

Quality of Life in Patients With Alcohol Use Disorder

Completed NA Last updated 31 July 2025
What this trial tests

NA trial testing questionnaires in Alcohol Use Disorder in 167 participants. Completed in 21 January 2025.

Timeline
25 March 2021
Primary endpoint
8 August 2024
21 January 2025

Quick facts

Lead sponsorHôpital le Vinatier
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment167
Start date25 March 2021
Primary completion8 August 2024
Estimated completion21 January 2025
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Hôpital le Vinatier — full company profile →

Who can join

Adults 18 to 70, any sex, with Alcohol Use Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary purpose of this study is to investigate the factors associated with quality of life of patients with alcohol use disorder (AUD) undergoing a detoxification program (cross-sectional analysis). The secondary purpose is (1) to identify the factors associated with change in quality of life between baseline and 6-month follow-up, and (2) to identify the factors associated with alcohol relapse at 6 months (longitudinal analyses).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of questionnaires

Trials testing the same drug.

Other recruiting trials for Alcohol Use Disorder

Currently open trials in the same condition.

Other Hôpital le Vinatier trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04748822.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing